PT1599461E - Tiolactonas como inibidores de naaladase - Google Patents

Info

Publication number

PT1599461E

PT1599461E PT04716834T PT04716834T PT1599461E PT 1599461 E PT1599461 E PT 1599461E PT 04716834 T PT04716834 T PT 04716834T PT 04716834 T PT04716834 T PT 04716834T PT 1599461 E PT1599461 E PT 1599461E

Authority

PT

Portugal

Prior art keywords

compound

disease

quot

substituted

substituents

Prior art date

2003-03-03

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003112 inhibitor Substances 0.000 title description 31
• 150000001875 compounds Chemical class 0.000 claims abstract description 127
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 95
• 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims abstract description 62
• 201000010099 disease Diseases 0.000 claims abstract description 54
• 208000035475 disorder Diseases 0.000 claims abstract description 41
• 208000010412 Glaucoma Diseases 0.000 claims abstract description 39
• 230000000694 effects Effects 0.000 claims abstract description 36
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 28
• 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 28
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
• 229930195712 glutamate Natural products 0.000 claims abstract description 27
• 201000011510 cancer Diseases 0.000 claims abstract description 19
• 208000023105 Huntington disease Diseases 0.000 claims abstract description 18
• 230000033115 angiogenesis Effects 0.000 claims abstract description 18
• 208000002193 Pain Diseases 0.000 claims abstract description 17
• 230000036407 pain Effects 0.000 claims abstract description 16
• 208000033808 peripheral neuropathy Diseases 0.000 claims abstract description 16
• 230000001537 neural effect Effects 0.000 claims abstract description 15
• 208000017442 Retinal disease Diseases 0.000 claims abstract description 14
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
• 208000017497 prostate disease Diseases 0.000 claims abstract description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
• 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 6
• 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 claims abstract 7
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 121
• 229960005181 morphine Drugs 0.000 claims description 59
• -1 benzylene Chemical group 0.000 claims description 50
• 125000001424 substituent group Chemical group 0.000 claims description 37
• 229910052739 hydrogen Inorganic materials 0.000 claims description 29
• 239000001257 hydrogen Substances 0.000 claims description 29
• 239000000902 placebo Substances 0.000 claims description 26
• 229940068196 placebo Drugs 0.000 claims description 26
• 150000002431 hydrogen Chemical class 0.000 claims description 24
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 23
• 239000003814 drug Substances 0.000 claims description 23
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 22
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
• 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 21
• 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 21
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 21
• 125000000217 alkyl group Chemical group 0.000 claims description 19
• 208000014674 injury Diseases 0.000 claims description 19
• 150000003839 salts Chemical class 0.000 claims description 19
• 241000124008 Mammalia Species 0.000 claims description 18
• 239000000126 substance Substances 0.000 claims description 17
• 210000001519 tissue Anatomy 0.000 claims description 17
• 125000005724 cycloalkenylene group Chemical group 0.000 claims description 15
• 229910052736 halogen Inorganic materials 0.000 claims description 15
• 150000002367 halogens Chemical class 0.000 claims description 15
• 208000019901 Anxiety disease Diseases 0.000 claims description 14
• 230000005764 inhibitory process Effects 0.000 claims description 14
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 14
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
• 208000027418 Wounds and injury Diseases 0.000 claims description 13
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
• 230000006378 damage Effects 0.000 claims description 12
• 230000004770 neurodegeneration Effects 0.000 claims description 12
• 208000012902 Nervous system disease Diseases 0.000 claims description 11
• 125000002947 alkylene group Chemical group 0.000 claims description 11
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
• 230000002792 vascular Effects 0.000 claims description 11
• 208000016192 Demyelinating disease Diseases 0.000 claims description 10
• 125000004450 alkenylene group Chemical group 0.000 claims description 10
• 125000003118 aryl group Chemical group 0.000 claims description 10
• 125000002993 cycloalkylene group Chemical group 0.000 claims description 10
• 238000002360 preparation method Methods 0.000 claims description 10
• 239000012453 solvate Substances 0.000 claims description 10
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 9
• 208000018737 Parkinson disease Diseases 0.000 claims description 9
• 125000003342 alkenyl group Chemical group 0.000 claims description 9
• 125000004419 alkynylene group Chemical group 0.000 claims description 9
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 8
• 230000015572 biosynthetic process Effects 0.000 claims description 8
• 125000003545 alkoxy group Chemical group 0.000 claims description 7
• 210000004556 brain Anatomy 0.000 claims description 7
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
• 150000004677 hydrates Chemical class 0.000 claims description 7
• 238000003384 imaging method Methods 0.000 claims description 7
• 206010027175 memory impairment Diseases 0.000 claims description 7
• 201000000980 schizophrenia Diseases 0.000 claims description 7
• 230000036506 anxiety Effects 0.000 claims description 6
• 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 claims description 6
• 239000003153 chemical reaction reagent Substances 0.000 claims description 6
• 239000003795 chemical substances by application Substances 0.000 claims description 6
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
• 230000002255 enzymatic effect Effects 0.000 claims description 6
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
• 208000004296 neuralgia Diseases 0.000 claims description 6
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
• 208000021722 neuropathic pain Diseases 0.000 claims description 6
• 229940127240 opiate Drugs 0.000 claims description 6
• 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 6
• 208000035473 Communicable disease Diseases 0.000 claims description 5
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 208000015181 infectious disease Diseases 0.000 claims description 5
• 208000027866 inflammatory disease Diseases 0.000 claims description 5
• YYXJMOQAESRPSE-UHFFFAOYSA-N 3-(2-oxothian-3-yl)propanoic acid Chemical compound OC(=O)CCC1CCCSC1=O YYXJMOQAESRPSE-UHFFFAOYSA-N 0.000 claims description 4
• 206010060862 Prostate cancer Diseases 0.000 claims description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
• 208000029028 brain injury Diseases 0.000 claims description 4
• 230000010261 cell growth Effects 0.000 claims description 4
• 238000001514 detection method Methods 0.000 claims description 4
• 125000004957 naphthylene group Chemical group 0.000 claims description 4
• 210000002569 neuron Anatomy 0.000 claims description 4
• GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims description 4
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
• 230000002265 prevention Effects 0.000 claims description 4
• 210000000278 spinal cord Anatomy 0.000 claims description 4
• 230000000638 stimulation Effects 0.000 claims description 4
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
• SWZSGEFGQYYIGV-UHFFFAOYSA-N 3-[(2-oxothian-3-yl)methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CC2C(SCCC2)=O)=C1 SWZSGEFGQYYIGV-UHFFFAOYSA-N 0.000 claims description 3
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
• 208000029147 Collagen-vascular disease Diseases 0.000 claims description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 3
• 206010061218 Inflammation Diseases 0.000 claims description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
• 210000001124 body fluid Anatomy 0.000 claims description 3
• 239000010839 body fluid Substances 0.000 claims description 3
• 229960003920 cocaine Drugs 0.000 claims description 3
• 208000018631 connective tissue disease Diseases 0.000 claims description 3
• 210000000981 epithelium Anatomy 0.000 claims description 3
• 210000002744 extracellular matrix Anatomy 0.000 claims description 3
• 230000000893 fibroproliferative effect Effects 0.000 claims description 3
• 210000000987 immune system Anatomy 0.000 claims description 3
• 230000004054 inflammatory process Effects 0.000 claims description 3
• 229910052740 iodine Inorganic materials 0.000 claims description 3
• 210000003734 kidney Anatomy 0.000 claims description 3
• 229960002715 nicotine Drugs 0.000 claims description 3
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
• 230000009529 traumatic brain injury Effects 0.000 claims description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
• 239000011782 vitamin Substances 0.000 claims description 3
• 235000013343 vitamin Nutrition 0.000 claims description 3
• 229940088594 vitamin Drugs 0.000 claims description 3
• 229930003231 vitamin Natural products 0.000 claims description 3
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
• OPWFMUIGBAFGOP-UHFFFAOYSA-N 3-(1-oxo-3,4-dihydrothiopyrano[3,4-b]indol-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC(N2C3=CC=CC=C3C3=C2C(SCC3)=O)=C1 OPWFMUIGBAFGOP-UHFFFAOYSA-N 0.000 claims description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
• 206010038389 Renal cancer Diseases 0.000 claims description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
• 206010057644 Testis cancer Diseases 0.000 claims description 2
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
• 208000000509 infertility Diseases 0.000 claims description 2
• 230000036512 infertility Effects 0.000 claims description 2
• 231100000535 infertility Toxicity 0.000 claims description 2
• 201000010982 kidney cancer Diseases 0.000 claims description 2
• 208000002780 macular degeneration Diseases 0.000 claims description 2
• 230000009689 neuronal regeneration Effects 0.000 claims description 2
• 201000003120 testicular cancer Diseases 0.000 claims description 2
• 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims 4
• 208000025966 Neurological disease Diseases 0.000 claims 3
• LXECNSMYNFWFCZ-UHFFFAOYSA-N 3-(1-oxo-3,4-dihydroisothiochromen-8-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C=3C(=O)SCCC=3C=CC=2)=C1 LXECNSMYNFWFCZ-UHFFFAOYSA-N 0.000 claims 1
• HNFONZNDOVCFPB-UHFFFAOYSA-N 3-[(1-oxo-3,4-dihydroisothiochromen-8-yl)oxymethyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(COC=2C=3C(=O)SCCC=3C=CC=2)=C1 HNFONZNDOVCFPB-UHFFFAOYSA-N 0.000 claims 1
• 208000029726 Neurodevelopmental disease Diseases 0.000 claims 1
• 230000037390 scarring Effects 0.000 claims 1
• VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 40
• 201000001119 neuropathy Diseases 0.000 abstract description 9
• 230000007823 neuropathy Effects 0.000 abstract description 9
• 230000005856 abnormality Effects 0.000 abstract 1
• 102100020995 Putative N-acetylated-alpha-linked acidic dipeptidase Human genes 0.000 description 52
• 241001465754 Metazoa Species 0.000 description 30
• 241000700159 Rattus Species 0.000 description 29
• 241000699670 Mus sp. Species 0.000 description 27
• 210000001508 eye Anatomy 0.000 description 27
• 239000000203 mixture Substances 0.000 description 19
• ISEYJGQFXSTPMQ-UHFFFAOYSA-N 2-(phosphonomethyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(O)=O ISEYJGQFXSTPMQ-UHFFFAOYSA-N 0.000 description 18
• 239000000835 fiber Substances 0.000 description 16
• 238000011161 development Methods 0.000 description 15
• 230000018109 developmental process Effects 0.000 description 15
• 241000699666 Mus <mouse, genus> Species 0.000 description 14
• 210000002469 basement membrane Anatomy 0.000 description 14
• OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 13
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
• 230000003502 anti-nociceptive effect Effects 0.000 description 12
• 229940079593 drug Drugs 0.000 description 12
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
• 239000003981 vehicle Substances 0.000 description 12
• 208000028867 ischemia Diseases 0.000 description 11
• 210000005036 nerve Anatomy 0.000 description 11
• 239000011780 sodium chloride Substances 0.000 description 11
• 210000004027 cell Anatomy 0.000 description 10
• 230000012010 growth Effects 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 229940126062 Compound A Drugs 0.000 description 9
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 230000007170 pathology Effects 0.000 description 9
• 210000001525 retina Anatomy 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• 210000003050 axon Anatomy 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 8
• 210000001328 optic nerve Anatomy 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 230000005855 radiation Effects 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 208000024827 Alzheimer disease Diseases 0.000 description 7
• 235000019441 ethanol Nutrition 0.000 description 7
• 230000003287 optical effect Effects 0.000 description 7
• 210000003668 pericyte Anatomy 0.000 description 7
• 239000007787 solid Substances 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• 230000008733 trauma Effects 0.000 description 7
• 239000004215 Carbon black (E152) Substances 0.000 description 6
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
• 206010027476 Metastases Diseases 0.000 description 6
• 238000005481 NMR spectroscopy Methods 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 210000002889 endothelial cell Anatomy 0.000 description 6
• 235000019439 ethyl acetate Nutrition 0.000 description 6
• 229930195733 hydrocarbon Natural products 0.000 description 6
• 208000020016 psychiatric disease Diseases 0.000 description 6
• 230000002207 retinal effect Effects 0.000 description 6
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 5
• 208000028389 Nerve injury Diseases 0.000 description 5
• 102000016387 Pancreatic elastase Human genes 0.000 description 5
• 108010067372 Pancreatic elastase Proteins 0.000 description 5
• 206010039710 Scleroderma Diseases 0.000 description 5
• 208000006011 Stroke Diseases 0.000 description 5
• 230000002491 angiogenic effect Effects 0.000 description 5
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 5
• 229960004640 memantine Drugs 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• 230000008764 nerve damage Effects 0.000 description 5
• 229910052760 oxygen Inorganic materials 0.000 description 5
• 239000001301 oxygen Substances 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 210000001210 retinal vessel Anatomy 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• FNLNSQHJKVQCBP-UHFFFAOYSA-N 2-(3-sulfanylpropyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CCCS FNLNSQHJKVQCBP-UHFFFAOYSA-N 0.000 description 4
• 208000000044 Amnesia Diseases 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• 239000005711 Benzoic acid Substances 0.000 description 4
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
• OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 239000008367 deionised water Substances 0.000 description 4
• 229910021641 deionized water Inorganic materials 0.000 description 4
• 230000006866 deterioration Effects 0.000 description 4
• 230000029087 digestion Effects 0.000 description 4
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
• 230000005670 electromagnetic radiation Effects 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• 210000000944 nerve tissue Anatomy 0.000 description 4
• 239000002858 neurotransmitter agent Substances 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
• 230000000144 pharmacologic effect Effects 0.000 description 4
• 230000036515 potency Effects 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 208000011117 substance-related disease Diseases 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• 208000007848 Alcoholism Diseases 0.000 description 3
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
• 108010036949 Cyclosporine Proteins 0.000 description 3
• 208000001613 Gambling Diseases 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• 208000026139 Memory disease Diseases 0.000 description 3
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
• 206010033128 Ovarian cancer Diseases 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 206010038923 Retinopathy Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 201000007930 alcohol dependence Diseases 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• 235000010233 benzoic acid Nutrition 0.000 description 3
• 239000007975 buffered saline Substances 0.000 description 3
• 239000006172 buffering agent Substances 0.000 description 3
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• 230000001186 cumulative effect Effects 0.000 description 3
• 238000004821 distillation Methods 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 230000009545 invasion Effects 0.000 description 3
• 208000017169 kidney disease Diseases 0.000 description 3
• 238000002595 magnetic resonance imaging Methods 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000010534 mechanism of action Effects 0.000 description 3
• 230000006984 memory degeneration Effects 0.000 description 3
• 208000023060 memory loss Diseases 0.000 description 3
• 206010028537 myelofibrosis Diseases 0.000 description 3
• 230000001717 pathogenic effect Effects 0.000 description 3
• 239000008363 phosphate buffer Substances 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 210000002307 prostate Anatomy 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 238000010898 silica gel chromatography Methods 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 210000004881 tumor cell Anatomy 0.000 description 3
• JKPYNGWTXQIZFC-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)benzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(C(O)=O)=C1 JKPYNGWTXQIZFC-UHFFFAOYSA-N 0.000 description 2
• USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 208000007122 AIDS-Associated Nephropathy Diseases 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• 206010059199 Anterior chamber cleavage syndrome Diseases 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
• MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 208000030814 Eating disease Diseases 0.000 description 2
• 208000019454 Feeding and Eating disease Diseases 0.000 description 2
• 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 2
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 206010070737 HIV associated nephropathy Diseases 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
• 208000029523 Interstitial Lung disease Diseases 0.000 description 2
• 206010023421 Kidney fibrosis Diseases 0.000 description 2
• 208000000185 Localized scleroderma Diseases 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
• 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 2
• 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 2
• 206010027982 Morphoea Diseases 0.000 description 2
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
• LWLSVNFEVKJDBZ-UHFFFAOYSA-N N-[4-(trifluoromethoxy)phenyl]-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide Chemical compound FC(OC1=CC=C(C=C1)NC(=O)N1CCC(CC1)CC1=CC(=CC=C1)OC1=NC=C(C=C1)C(F)(F)F)(F)F LWLSVNFEVKJDBZ-UHFFFAOYSA-N 0.000 description 2
• OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 2
• 229910003251 Na K Inorganic materials 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 208000030768 Optic nerve injury Diseases 0.000 description 2
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
• UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• 206010034158 Pathological gambling Diseases 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 208000018262 Peripheral vascular disease Diseases 0.000 description 2
• 206010034912 Phobia Diseases 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 241000097929 Porphyria Species 0.000 description 2
• 208000010642 Porphyrias Diseases 0.000 description 2
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 208000003782 Raynaud disease Diseases 0.000 description 2
• 208000012322 Raynaud phenomenon Diseases 0.000 description 2
• 241000606701 Rickettsia Species 0.000 description 2
• 206010039705 Scleritis Diseases 0.000 description 2
• 206010039966 Senile dementia Diseases 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 208000000323 Tourette Syndrome Diseases 0.000 description 2
• 208000016620 Tourette disease Diseases 0.000 description 2
• 206010070863 Toxicity to various agents Diseases 0.000 description 2
• 241000223996 Toxoplasma Species 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 206010052428 Wound Diseases 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 125000002723 alicyclic group Chemical group 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 238000000540 analysis of variance Methods 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 230000036528 appetite Effects 0.000 description 2
• 235000019789 appetite Nutrition 0.000 description 2
• 206010003074 arachnoiditis Diseases 0.000 description 2
• 230000003542 behavioural effect Effects 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 235000010290 biphenyl Nutrition 0.000 description 2
• 239000004305 biphenyl Substances 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 230000036770 blood supply Effects 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 150000001649 bromium compounds Chemical class 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 210000003161 choroid Anatomy 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 208000019425 cirrhosis of liver Diseases 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 210000000795 conjunctiva Anatomy 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 201000005637 crescentic glomerulonephritis Diseases 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 125000000753 cycloalkyl group Chemical group 0.000 description 2
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
• LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
• 229960000860 dapsone Drugs 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 208000033679 diabetic kidney disease Diseases 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 230000003292 diminished effect Effects 0.000 description 2
• 235000014632 disordered eating Nutrition 0.000 description 2
• 230000004406 elevated intraocular pressure Effects 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
• 208000013403 hyperactivity Diseases 0.000 description 2
• 230000036737 immune function Effects 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 150000004694 iodide salts Chemical class 0.000 description 2
• 108010076560 isospaglumic acid Proteins 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 230000007257 malfunction Effects 0.000 description 2
• 230000003340 mental effect Effects 0.000 description 2
• 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 2
• RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 208000001022 morbid obesity Diseases 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 210000003007 myelin sheath Anatomy 0.000 description 2
• 230000023105 myelination Effects 0.000 description 2
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
• 230000001067 neuroprotector Effects 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 230000006959 non-competitive inhibition Effects 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000012285 osmium tetroxide Substances 0.000 description 2
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 208000019906 panic disease Diseases 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 229960001412 pentobarbital Drugs 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 201000000317 pneumocystosis Diseases 0.000 description 2
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 230000001242 postsynaptic effect Effects 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 235000019833 protease Nutrition 0.000 description 2
• 238000005086 pumping Methods 0.000 description 2
• BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 201000002793 renal fibrosis Diseases 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 231100000241 scar Toxicity 0.000 description 2
• 230000035807 sensation Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 201000001716 specific phobia Diseases 0.000 description 2
• 208000020431 spinal cord injury Diseases 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 201000006152 substance dependence Diseases 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 230000000946 synaptic effect Effects 0.000 description 2
• 208000006379 syphilis Diseases 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
• 230000008719 thickening Effects 0.000 description 2
• 208000037816 tissue injury Diseases 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 239000003039 volatile agent Substances 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• ZEHYJZXQEQOSON-AATRIKPKSA-N (e)-1-chloro-3-ethylpent-1-en-4-yn-3-ol Chemical compound CCC(O)(C#C)\C=C\Cl ZEHYJZXQEQOSON-AATRIKPKSA-N 0.000 description 1
• CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
• VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
• VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
• QNLDTXPVZPRSAM-UHFFFAOYSA-N 17146-95-1 Chemical compound CC(O)C(O)=O.C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 QNLDTXPVZPRSAM-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• SMGZBRVSYVJHCB-UHFFFAOYSA-N 2-(2-sulfanylethyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CCS SMGZBRVSYVJHCB-UHFFFAOYSA-N 0.000 description 1
• FIILSNMCZCETMG-UHFFFAOYSA-N 2-(3-carboxyphenyl)-6-(2-sulfanylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C(=C(CCS)C=CC=2)C(O)=O)=C1 FIILSNMCZCETMG-UHFFFAOYSA-N 0.000 description 1
• RAROSELKYMGMIQ-UHFFFAOYSA-N 2-[3-(trityldisulfanyl)propyl]pentanedioic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SSCCCC(CCC(=O)O)C(O)=O)C1=CC=CC=C1 RAROSELKYMGMIQ-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• ZTTRAVPRWXCCDT-UHFFFAOYSA-N 3-tert-butyl-5-(2-carboxy-5-sulfanylpentyl)benzoic acid Chemical compound CC(C)(C)C1=CC(CC(CCCS)C(O)=O)=CC(C(O)=O)=C1 ZTTRAVPRWXCCDT-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 206010000050 Abdominal adhesions Diseases 0.000 description 1
• 208000012260 Accidental injury Diseases 0.000 description 1
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000008811 Agoraphobia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 206010002859 Anxiety disorder due to a general medical condition Diseases 0.000 description 1
• 206010002945 Aphakia Diseases 0.000 description 1
• 101001044245 Arabidopsis thaliana Insulin-degrading enzyme-like 1, peroxisomal Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
• 208000000412 Avitaminosis Diseases 0.000 description 1
• 208000010059 Axenfeld-Rieger syndrome Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000006373 Bell palsy Diseases 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 206010004664 Biliary fibrosis Diseases 0.000 description 1
• 206010004716 Binge eating Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000222173 Candida parapsilosis Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 244000025254 Cannabis sativa Species 0.000 description 1
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
• 102000005367 Carboxypeptidases Human genes 0.000 description 1
• 108010006303 Carboxypeptidases Proteins 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 201000007336 Cryptococcosis Diseases 0.000 description 1
• 241000221204 Cryptococcus neoformans Species 0.000 description 1
• 208000008953 Cryptosporidiosis Diseases 0.000 description 1
• 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
• PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 206010012645 Diabetic autonomic neuropathy Diseases 0.000 description 1
• 206010012676 Diabetic mononeuropathy Diseases 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
• 102000004860 Dipeptidases Human genes 0.000 description 1
• 108090001081 Dipeptidases Proteins 0.000 description 1
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010049119 Emotional distress Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
• 206010015084 Episcleritis Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 208000031969 Eye Hemorrhage Diseases 0.000 description 1
• 206010016228 Fasciitis Diseases 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 206010016845 Foetal alcohol syndrome Diseases 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 208000011688 Generalised anxiety disease Diseases 0.000 description 1
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
• 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
• 108010027915 Glutamate Receptors Proteins 0.000 description 1
• 102000018899 Glutamate Receptors Human genes 0.000 description 1
• 229940122459 Glutamate antagonist Drugs 0.000 description 1
• JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
• 241000228404 Histoplasma capsulatum Species 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101100188749 Homo sapiens OPN1MW gene Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 206010021135 Hypovitaminosis Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 206010065390 Inflammatory pain Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 208000015592 Involuntary movements Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 241000222722 Leishmania <genus> Species 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 241000186781 Listeria Species 0.000 description 1
• 241000883511 Lophophora williamsii Species 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
• 206010025538 Malignant ascites Diseases 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 208000009857 Microaneurysm Diseases 0.000 description 1
• 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000186362 Mycobacterium leprae Species 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 102100038610 Myeloperoxidase Human genes 0.000 description 1
• 108090000235 Myeloperoxidases Proteins 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 108090000189 Neuropeptides Proteins 0.000 description 1
• 102000003797 Neuropeptides Human genes 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 206010057852 Nicotine dependence Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 208000026251 Opioid-Related disease Diseases 0.000 description 1
• 241000606693 Orientia tsutsugamushi Species 0.000 description 1
• 206010033307 Overweight Diseases 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010033664 Panic attack Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 201000000016 Peters anomaly Diseases 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 241000233870 Pneumocystis Species 0.000 description 1
• 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
• 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 208000037062 Polyps Diseases 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 208000024777 Prion disease Diseases 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 206010037520 Pupillary block Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 208000037673 Rare dementia Diseases 0.000 description 1
• 208000035977 Rare disease Diseases 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 201000007527 Retinal artery occlusion Diseases 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
• 241000606697 Rickettsia prowazekii Species 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 208000032023 Signs and Symptoms Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010041250 Social phobia Diseases 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 206010042008 Stereotypy Diseases 0.000 description 1
• 208000013200 Stress disease Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
• 231100000643 Substance intoxication Toxicity 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 208000025569 Tobacco Use disease Diseases 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 241000223997 Toxoplasma gondii Species 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 206010044708 Trypanosomal infections Diseases 0.000 description 1
• COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
• 201000004810 Vascular dementia Diseases 0.000 description 1
• 206010047163 Vasospasm Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 150000001241 acetals Chemical class 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000026345 acute stress disease Diseases 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 201000002454 adrenal cortex cancer Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 208000028505 alcohol-related disease Diseases 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 229960004538 alprazolam Drugs 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 208000008303 aniridia Diseases 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000002249 anxiolytic agent Substances 0.000 description 1
• 230000000949 anxiolytic effect Effects 0.000 description 1
• 229940005530 anxiolytics Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 230000000712 assembly Effects 0.000 description 1
• 238000000429 assembly Methods 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 229940125717 barbiturate Drugs 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 208000014679 binge eating disease Diseases 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 238000011685 brown norway rat Methods 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 229940055022 candida parapsilosis Drugs 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 206010007776 catatonia Diseases 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 201000005849 central retinal artery occlusion Diseases 0.000 description 1
• 201000005667 central retinal vein occlusion Diseases 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 208000036319 cervical spondylosis Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 229960004782 chlordiazepoxide Drugs 0.000 description 1
• ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 125000002378 chlorosyl group Chemical group O=Cl[*] 0.000 description 1
• 238000007813 chromatographic assay Methods 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 230000037326 chronic stress Effects 0.000 description 1
• 210000004240 ciliary body Anatomy 0.000 description 1
• 230000001886 ciliary effect Effects 0.000 description 1
• 230000009194 climbing Effects 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940126208 compound 22 Drugs 0.000 description 1
• JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
• 231100000867 compulsive behavior Toxicity 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 150000001886 cortisols Chemical class 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
• 239000004913 cyclooctene Substances 0.000 description 1
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 231100000409 cytocidal Toxicity 0.000 description 1
• 230000000445 cytocidal effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 229940080861 demerol Drugs 0.000 description 1
• 230000003001 depressive effect Effects 0.000 description 1
• QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 description 1
• 150000008050 dialkyl sulfates Chemical class 0.000 description 1
• 229960002069 diamorphine Drugs 0.000 description 1
• 229960003529 diazepam Drugs 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
• 229940099212 dilaudid Drugs 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 150000002009 diols Chemical class 0.000 description 1
• GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 229940072340 dolophine Drugs 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 238000002635 electroconvulsive therapy Methods 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000003821 enantio-separation Methods 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 210000000871 endothelium corneal Anatomy 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 229940125532 enzyme inhibitor Drugs 0.000 description 1
• 239000003822 epoxy resin Substances 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• 229960002428 fentanyl Drugs 0.000 description 1
• PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 208000026934 fetal alcohol spectrum disease Diseases 0.000 description 1
• 201000007794 fetal alcohol syndrome Diseases 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 238000005188 flotation Methods 0.000 description 1
• GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 208000029364 generalized anxiety disease Diseases 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
• 230000000848 glutamatergic effect Effects 0.000 description 1
• 229960002972 glutethimide Drugs 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 239000000380 hallucinogen Substances 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000001072 heteroaryl group Chemical group 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
• 229960000240 hydrocodone Drugs 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 229960001410 hydromorphone Drugs 0.000 description 1
• 125000001867 hydroperoxy group Chemical group [*]OO[H] 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 201000001948 hypertensive retinopathy Diseases 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 230000000642 iatrogenic effect Effects 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 230000035987 intoxication Effects 0.000 description 1
• 231100000566 intoxication Toxicity 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 125000001812 iodosyl group Chemical group O=I[*] 0.000 description 1
• 125000002512 iodyl group Chemical group O=I(=O)[*] 0.000 description 1
• 210000000554 iris Anatomy 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 210000004558 lewy body Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 231100000863 loss of memory Toxicity 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 208000024714 major depressive disease Diseases 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
• 229960001797 methadone Drugs 0.000 description 1
• 229960001252 methamphetamine Drugs 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 230000002969 morbid Effects 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000004973 motor coordination Effects 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 208000022155 mycobacterium avium complex disease Diseases 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000004081 narcotic agent Substances 0.000 description 1
• 239000004084 narcotic analgesic agent Substances 0.000 description 1
• 230000017095 negative regulation of cell growth Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 210000001640 nerve ending Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 231100000189 neurotoxic Toxicity 0.000 description 1
• 230000002887 neurotoxic effect Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 201000005040 opiate dependence Diseases 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 235000013348 organic food Nutrition 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 229960004535 oxazepam Drugs 0.000 description 1
• ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 229960002085 oxycodone Drugs 0.000 description 1
• 229960005118 oxymorphone Drugs 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 201000003042 peeling skin syndrome Diseases 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 229960000482 pethidine Drugs 0.000 description 1
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920000647 polyepoxide Polymers 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
• 230000017363 positive regulation of growth Effects 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• 208000028173 post-traumatic stress disease Diseases 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 201000008752 progressive muscular atrophy Diseases 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000009979 protective mechanism Effects 0.000 description 1
• 230000003304 psychophysiological effect Effects 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 239000002534 radiation-sensitizing agent Substances 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000036387 respiratory rate Effects 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 210000003994 retinal ganglion cell Anatomy 0.000 description 1
• 230000004232 retinal microvasculature Effects 0.000 description 1
• 230000004286 retinal pathology Effects 0.000 description 1
• 208000004644 retinal vein occlusion Diseases 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 230000001020 rhythmical effect Effects 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 210000003786 sclera Anatomy 0.000 description 1
• 210000001625 seminal vesicle Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 238000002603 single-photon emission computed tomography Methods 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 206010040882 skin lesion Diseases 0.000 description 1
• 231100000444 skin lesion Toxicity 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 238000002791 soaking Methods 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 208000005801 spondylosis Diseases 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000007447 staining method Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 201000005428 steroid-induced glaucoma Diseases 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000000859 sublimation Methods 0.000 description 1
• 230000008022 sublimation Effects 0.000 description 1
• 201000009032 substance abuse Diseases 0.000 description 1
• 231100000736 substance abuse Toxicity 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 210000002504 synaptic vesicle Anatomy 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229940066690 talwin Drugs 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 229960003188 temazepam Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000005031 thiocyano group Chemical group S(C#N)* 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 210000002978 thoracic duct Anatomy 0.000 description 1
• 230000009424 thromboembolic effect Effects 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
• 229960005001 ticlopidine Drugs 0.000 description 1
• 229950003937 tolonium Drugs 0.000 description 1
• HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 238000004627 transmission electron microscopy Methods 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• 230000001573 trophoblastic effect Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 201000010653 vesiculitis Diseases 0.000 description 1
• 229940000146 vicodin Drugs 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 208000030401 vitamin deficiency disease Diseases 0.000 description 1
• 210000004127 vitreous body Anatomy 0.000 description 1
• 230000001755 vocal effect Effects 0.000 description 1
• 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1